News

Sudhakar Bangera and Latha MS discuss how in the past medical devices in India were clubbed with regulations for new drugs, biologicals and vaccines, but how new regulations are bringing new and more devices to the area.

The importance of applying change management techniques throughout the preparation, planning, and execution of RBM and RBQM approaches.

Outlining a resource planning and scheduling model, using the example of an analytical department in drug development.

President and CEO of Cyclacel, Spiro Rombotis, discusses why targeting cyclin-dependent kinases and the DNA repair pathway could enhance care across various oncology indications.

As elections near, politicians in Europe make promises to prioritize the fight against cancer.

FDA leaders urge developers, researchers, and research sponsors to help promote policies and programs to streamline clinical research to develop new medical products at reduced costs.

What small “nudges” can serve as reminders and relevant motivators to help patients meet their goals, talk to a physician, explore a clinical trial, or stick with a treatment?

Click the title above to open the Applied Clinical Trials May 2019 issue in an interactive PDF format.

Transparency in clinical trials doesn't have to be difficult but requires attention writes Thomas Wicks, Chief Strategy Officer for TrialScope. Smaller organizations tend to lag in their commitments to clinical data sharing and be non-compliant with regulations, but the trend is shifting.